- Home
- NGNE vs ILPT Comparison
NGNE vs ILPT Comparison
Compare NGNE & ILPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- ILPT
- Stock Information
- Founded
- NGNE 2003
- ILPT 2017
- Country
- NGNE United States
- ILPT United States
- Employees
- NGNE N/A
- ILPT N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- ILPT Real Estate Investment Trusts
- Sector
- NGNE Health Care
- ILPT Real Estate
- Exchange
- NGNE Nasdaq
- ILPT Nasdaq
- Market Cap
- NGNE 325.3M
- ILPT 380.8M
- IPO Year
- NGNE N/A
- ILPT 2018
- Fundamental
- Price
- NGNE $18.48
- ILPT $6.16
- Analyst Decision
- NGNE Strong Buy
- ILPT
- Analyst Count
- NGNE 7
- ILPT 0
- Target Price
- NGNE $41.86
- ILPT N/A
- AVG Volume (30 Days)
- NGNE 110.1K
- ILPT 538.8K
- Earning Date
- NGNE 08-11-2025
- ILPT 10-28-2025
- Dividend Yield
- NGNE N/A
- ILPT 0.65%
- EPS Growth
- NGNE N/A
- ILPT N/A
- EPS
- NGNE N/A
- ILPT N/A
- Revenue
- NGNE N/A
- ILPT $443,468,000.00
- Revenue This Year
- NGNE N/A
- ILPT $3.44
- Revenue Next Year
- NGNE N/A
- ILPT $1.78
- P/E Ratio
- NGNE N/A
- ILPT N/A
- Revenue Growth
- NGNE N/A
- ILPT 0.36
- 52 Week Low
- NGNE $6.88
- ILPT $2.45
- 52 Week High
- NGNE $74.49
- ILPT $6.32
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- ILPT 62.18
- Support Level
- NGNE $19.59
- ILPT $5.83
- Resistance Level
- NGNE $20.46
- ILPT $6.16
- Average True Range (ATR)
- NGNE 1.23
- ILPT 0.22
- MACD
- NGNE -0.20
- ILPT -0.01
- Stochastic Oscillator
- NGNE 13.37
- ILPT 78.38
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.